Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197

Lori J. Goldstein, Anne O'Neill, Joseph A. Sparano, Edith A. Perez, Lawrence N. Shulman, Silvana Martino, Nancy E. Davidson

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American breast cancer intergroup trial E 2197'. Together they form a unique fingerprint.

Medicine & Life Sciences